Berlin - Private equity firm capiton has closed a top-up single-asset fund for its fast-growing portfolio company KD Pharma Group (KD Pharma). This top-up fund will provide KD Pharma with the equity financing for additional strategic investments, in particular add-on acquisitions as well as organic growth initiatives to transfer KD Pharma‘s unique technology and service portfolio from its core omega-3 market to adjacent market segments. All parties involved have agreed not to disclose any details of the transaction.
A CMS team provided comprehensive legal advice to capiton regarding the investment in KD Pharma. capiton is a long-standing client and regularly relies on the expertise of CMS. The team also advised capiton on Germany's first GP-led single-asset secondary transaction which also involved KD Pharma Group.
CMS Germany
Dr. Eva Annett Grigoleit, Partner, Berlin
Dr. Igor Stenzel, Partner, Berlin
Patrick M Lühr, Counsel, Berlin,
Fabian Mayer, Senior Associate, Berlin, all Corporate/M&A
Dr. Jörn Witt, Partner, Hamburg,
Dr. Roland Wiring, Partner, Hamburg
Dr. Susanne Pech, Counsel, Hamburg, all Regulatory
Dr. Rolf Hempel, Partner, Stuttgart, Competition & EU
Press Contact
presse@cms-hs.com
